Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.
Christopher Willett, MD, of Duke Cancer Center, discusses short and long courses of treatment, neoadjuvant chemotherapy with or without radiation, and organ preservation without surgery.
Kenneth Anderson, MD, of Dana-Farber Cancer Institute, discusses how the many advances in the treatment of multiple myeloma affect current and future clinical practice.
Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.
Nadeem Abu-Rustum, MD, of Memorial Sloan Kettering Cancer Center, discusses improvements in fertility-sparing surgery for young women, advances in lymph node assessment, and the evolving role of chemotherapy and radiation.
Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
